Articles
What challenges do pharma companies face that risk limiting their ability to capitalize on this unique opportunity?
Companies are limited in the opportunities to in-licensing more clinical and commercially viable assets due to commercial capacity and capability constraints. However, by not exploring in-licensing opportunities, large pharma is missing out on opportunities for meaningful…
Overcome In-Licensing Challenges with EVERSANA
Increasing the throughput of commercialized in-licensed assets can have a multi-billion-dollar impact on valuations and create significant funding pools for further pipeline and business development initiatives. EVERSANA’s in-licensing capabilities were designed to eliminate the capacity and…
In-Licensing – A Once-in-a-Lifetime Moment of Market Conditions
Faruk Abdullah, General Manager, Advisory Services shares insights on the once-in-a-lifetime moment of market macro dynamics, making in-licensing opportunities. The opportunity at hand for large pharma has been created by the once-in-a-lifetime, current market dynamics. These…
Why is in-licensing such an important growth lever for companies?
In-licensing is a significant growth lever for a variety of reasons, including: Serving as a risk mitigation tool Reinforce a company’s therapeutic area footprint Serving as a growth catalyst channel to further diversify your pipeline and…